<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39352003</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>01</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1552-5279</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Oct</Month><Day>01</Day></PubDate></JournalIssue><Title>Alzheimer's &amp; dementia : the journal of the Alzheimer's Association</Title><ISOAbbreviation>Alzheimers Dement</ISOAbbreviation></Journal><ArticleTitle>Cerebral small vessel injury in mice with damage to ACE2-expressing cerebral vascular endothelial cells and post COVID-19 patients.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1002/alz.14279</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">The angiotensin-converting enzyme 2 (ACE2), which is expressed in cerebral vascular endothelial cells (CVECs), has been currently identified as a functional receptor for SARS-CoV-2.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We specifically induced injury to ACE2-expressing CVECs in mice and evaluated the effects of such targeted damage through magnetic resonance imaging (MRI) and cognitive behavioral tests. In parallel, we recruited a single-center cohort of COVID-19 survivors and further assessed their brain microvascular injury based on cognition and emotional scales, cranial MRI scans, and blood proteomic measurements.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Here, we show an array of pathological and behavioral alterations characteristic of cerebral small vessel disease (CSVD) in mice that targeted damage to ACE2-expressing CVECs, and COVID-19 survivors. These CSVD-like manifestations persist for at least 7 months post-recovery from COVID-19.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">Our findings suggest that SARS-CoV-2 may induce cerebral small vessel damage with persistent sequelae, underscoring the imperative for heightened clinical vigilance in mitigating or treating SARS-CoV-2-mediated cerebral endothelial injury throughout infection and convalescence.</AbstractText><AbstractText Label="HIGHLIGHTS" NlmCategory="CONCLUSIONS">Cerebral small vessel disease-associated changes were observed after targeted damage to angiotensin-converting enzyme 2-expressing cerebral vascular endothelial cells. SARS-CoV-2 may induce cerebral small vessel damage with persistent sequelae. Clinical vigilance is needed in preventing SARS-CoV-2-induced cerebral endothelial damage during infection and recovery.</AbstractText><CopyrightInformation>© 2024 The Author(s). Alzheimer's &amp; Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Jieping</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zuo</LastName><ForeName>Xin</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Neurology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Anhui Province Key Laboratory of Biomedical Imaging and Intelligent Processing, Institute of Artificial Intelligence, Hefei Comprehensive National Science Center, Hefei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cai</LastName><ForeName>Aoling</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Key Laboratory of Magnetic Resonance in Biological Systems, State Key Laboratory of Magnetic Resonance and Atomic and Molecular Physics, National Center for Magnetic Resonance in Wuhan, Wuhan Institute of Physics and Mathematics, Innovation Academy for Precision Measurement Science and Technology, Chinese Academy of Sciences-Wuhan National Laboratory for Optoelectronics, Wuhan, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Affiliated Changzhou Second People's Hospital of Nanjing Medical University, Changzhou Second People's Hospital, Changzhou Medical Center, Nanjing Medical University, Changzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xiao</LastName><ForeName>Fang</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Radiology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Zhenyu</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Neurology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Rui</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miao</LastName><ForeName>Chenjian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neurology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Chen</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neurology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zheng</LastName><ForeName>Xingxing</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Neurology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Jie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Key Laboratory of Magnetic Resonance in Biological Systems, State Key Laboratory of Magnetic Resonance and Atomic and Molecular Physics, National Center for Magnetic Resonance in Wuhan, Wuhan Institute of Physics and Mathematics, Innovation Academy for Precision Measurement Science and Technology, Chinese Academy of Sciences-Wuhan National Laboratory for Optoelectronics, Wuhan, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Chinese Academy of Sciences, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ding</LastName><ForeName>Xiaoling</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Neurology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xiong</LastName><ForeName>Wei</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Neurology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Anhui Province Key Laboratory of Biomedical Imaging and Intelligent Processing, Institute of Artificial Intelligence, Hefei Comprehensive National Science Center, Hefei, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Anhui Province Key Laboratory of Biomedical Aging Research, Hefei, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CAS Key Laboratory of Brain Function and Disease, Hefei, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>2021YFA0804900</GrantID><Agency>National Key R&amp;D Program of China</Agency><Country /></Grant><Grant><GrantID>2020YFA0112203</GrantID><Agency>National Key R&amp;D Program of China</Agency><Country /></Grant><Grant><GrantID>32225020</GrantID><Agency>National Natural Science Foundation of China</Agency><Country /></Grant><Grant><GrantID>91849206</GrantID><Agency>National Natural Science Foundation of China</Agency><Country /></Grant><Grant><GrantID>92049304</GrantID><Agency>National Natural Science Foundation of China</Agency><Country /></Grant><Grant><GrantID>32121002</GrantID><Agency>National Natural Science Foundation of China</Agency><Country /></Grant><Grant><GrantID>XDB39050000</GrantID><Agency>the Strategic Priority Research Program of the Chinese Academy of Sciences</Agency><Country /></Grant><Grant><GrantID>ZDBS-LY-SM002</GrantID><Agency>Key Research Program of Frontier Science</Agency><Country /></Grant><Grant><GrantID>JCTD-2018-20</GrantID><Agency>CAS Interdisciplinary Innovation Team</Agency><Country /></Grant><Grant><Agency>Youth Innovation Promotion Association CAS</Agency><Country /></Grant><Grant><GrantID>YD910000200</GrantID><Agency>USTC Research Funds of the Double First-Class Initiative</Agency><Country /></Grant><Grant><GrantID>YSBR-013</GrantID><Agency>CAS Project for Young Scientists in Basic Research</Agency><Country /></Grant><Grant><Agency>Hefei Comprehensive National Science Center Hefei Brain Project</Agency><Country /></Grant><Grant><GrantID>WK9110000098</GrantID><Agency>Fundamental Research Funds for the Central Universities</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Alzheimers Dement</MedlineTA><NlmUniqueID>101231978</NlmUniqueID><ISSNLinking>1552-5260</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID‐19 convalescent</Keyword><Keyword MajorTopicYN="N">angiotensin‐converting enzyme 2</Keyword><Keyword MajorTopicYN="N">cerebral small vessel disease</Keyword><Keyword MajorTopicYN="N">cerebral small vessels impairment</Keyword><Keyword MajorTopicYN="N">cerebral vascular endothelial cells</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>8</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>2</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>1</Day><Hour>16</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>1</Day><Hour>16</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>1</Day><Hour>7</Hour><Minute>53</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39352003</ArticleId><ArticleId IdType="doi">10.1002/alz.14279</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Davis HE, McCorkell L, Vogel JM, et al. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023;21(6):133‐146.</Citation></Reference><Reference><Citation>Xu E, Xie Y, Al‐Aly Z. Long‐term neurologic outcomes of COVID‐19. Nat Med. 2022;28:2406‐2415.</Citation></Reference><Reference><Citation>Taquet M, Geddes JR, Husain M, et al. 6‐month neurological and psychiatric outcomes in 236 379 survivors of COVID‐19: a retrospective cohort study using electronic health records. Lancet Psychiatry. 2021;8(5):416‐427.</Citation></Reference><Reference><Citation>Ellul MA, Benjamin L, Singh B, et al. Neurological associations of COVID‐19. Lancet Neurol. 2020;19(9):767‐783.</Citation></Reference><Reference><Citation>Pandharipande P, Williams Roberson S, Harrison FE, et al. Mitigating neurological, cognitive, and psychiatric sequelae of COVID‐19‐related critical illness. Lancet Respir Med. 2023;11(8):726‐738.</Citation></Reference><Reference><Citation>Cannistraro RJ, Badi M, Eidelman BH, et al. CNS small vessel disease A clinical review. Neurology. 2019;92(24):1146‐1156.</Citation></Reference><Reference><Citation>Pantoni L. Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges. Lancet Neurol. 2010;9(7):689‐701.</Citation></Reference><Reference><Citation>Li Q, Yang Y, Reis C, et al. Cerebral small vessel disease. Cell Transplant. 2018;27(12):1711‐1722.</Citation></Reference><Reference><Citation>Cuadrado‐Godia E, Dwivedi P, Sharma S, et al. Cerebral Small vessel disease: a review focusing on pathophysiology, biomarkers, and machine learning strategies. J Stroke. 2018;20(3):302‐320.</Citation></Reference><Reference><Citation>Cai M, Xie Y, Topol EJ, et al. Three‐year outcomes of post‐acute sequelae of COVID‐19. Nat Med. 2024;30(6):1564‐1573.</Citation></Reference><Reference><Citation>Mehandru S, Merad M. Pathological sequelae of long‐haul COVID. Nat Immunol. 2022;23(2):194‐202.</Citation></Reference><Reference><Citation>Han XC, Ye Q. Kidney involvement in COVID‐19 and its treatments. J Med Virol. 2021;93(3):1387‐1395.</Citation></Reference><Reference><Citation>Seymen CM. The other side of COVID‐19 pandemic: effects on male fertility. J Med Virol. 2021;93(3):1396‐1402.</Citation></Reference><Reference><Citation>Hong B, Li M, Fan H. SARS‐CoV‐2 Omicron subvariants from BA.2 to BA.2.86 and JN.1: strong lung infection ability and evolving immune escape capacity. MedComm. 2024;5(7):e578.</Citation></Reference><Reference><Citation>Proust A, Queval CJ, Harvey R, et al. Differential effects of SARS‐CoV‐2 variants on central nervous system cells and blood‐brain barrier functions. J Neuroinflammation. 2023;20(1):184.</Citation></Reference><Reference><Citation>Lee MH, Perl DP, Steiner J, et al. Neurovascular injury with complement activation and inflammation in COVID‐19. Brain. 2022;145(7):2555‐2568.</Citation></Reference><Reference><Citation>Paniz‐Mondolfi A, Bryce C, Grimes Z, et al. Central nervous system involvement by severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2). J Med Virol. 2020;92(7):699‐702.</Citation></Reference><Reference><Citation>Von Weyhern CH, Kaufmann I, Neff F, et al. Early evidence of pronounced brain involvement in fatal COVID‐19 outcomes. Lancet. 2020;395(10241):E109‐E109.</Citation></Reference><Reference><Citation>Baig AM, Khaleeq A, Ali U, et al. Evidence of the COVID‐19 virus targeting the CNS: tissue distribution, host‐virus interaction, and proposed neurotropic mechanisms. Acs Chem Neurosci. 2020;11(7):995‐998.</Citation></Reference><Reference><Citation>Varga Z, Flammer AJ, Steiger P, et al. Endothelial cell infection and endotheliitis in COVID‐19. Lancet. 2020;395(10234):1417‐1418.</Citation></Reference><Reference><Citation>Aghagoli G, Marin BG, Katchur NJ, et al. Neurological involvement in COVID‐19 and potential mechanisms: a review. Neurocrit Care. 2021;34(3):1062‐1071.</Citation></Reference><Reference><Citation>Nieuwland JM, Nutma E, Philippens I, et al. Longitudinal positron emission tomography and postmortem analysis reveals widespread neuroinflammation in SARS‐CoV‐2 infected rhesus macaques. J Neuroinflammation. 2023;20(1):179.</Citation></Reference><Reference><Citation>Erickson MA, Rhea EM, Knopp RC, et al. Interactions of SARS‐CoV‐2 with the blood‐brain barrier. Int J Mol Sci. 2021;22(5):2681.</Citation></Reference><Reference><Citation>Monteil V, Kwon H, Prado P, et al. Inhibition of SARS‐CoV‐2 infections in engineered human tissues using clinical‐grade soluble human ACE2. Cell. 2020;181(4):905‐913.</Citation></Reference><Reference><Citation>Conde JN, Schutt WR, Gorbunova EE, et al. Recombinant ACE2 expression is required for SARS‐CoV‐2 to infect primary human endothelial cells and induce inflammatory and procoagulative responses. Mbio. 2020;11(6):e03185‐20.</Citation></Reference><Reference><Citation>Liu MY, Zheng B, Zhang Y, et al. Role and mechanism of angiotensin‐converting enzyme 2 in acute lung injury in coronavirus disease 2019. Chronic Dis Transl Med. 2020;6(2):98‐105.</Citation></Reference><Reference><Citation>Jackson CB, Farzan M, Chen B, et al. Mechanisms of SARS‐CoV‐2 entry into cells. Nat Rev Mol Cell Bio. 2022;23(1):3‐20.</Citation></Reference><Reference><Citation>Crackower MA, Sarao R, Oudit GY, et al. Angiotensin‐converting enzyme 2 is an essential regulator of heart function. Nature. 2002;417(6891):822‐828.</Citation></Reference><Reference><Citation>Donoghue M, Hsieh F, Baronas E, et al. A novel angiotensin‐converting enzyme‐related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1‐9. Circ Res. 2000;87(5):E1‐E9.</Citation></Reference><Reference><Citation>Bryce C, Grimes Z, Pujadas E, et al. Pathophysiology of SARS‐CoV‐2: the Mount Sinai COVID‐19 autopsy experience. Modern Pathol. 2021;34(8):1456‐1467.</Citation></Reference><Reference><Citation>Tai WB, He L, Zhang XJ, et al. Characterization of the receptor‐binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine. Cell Mol Immunol. 2020;17(6):613‐620.</Citation></Reference><Reference><Citation>Walls AC, Park YJ, Tortorici MA, et al. Structure, function, and antigenicity of the SARS‐CoV‐2 spike glycoprotein. Cell. 2020;181(2):281‐292.</Citation></Reference><Reference><Citation>Hoffmann M, Kleine‐Weber H, Schroeder S, et al. SARS‐CoV‐2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271‐280.</Citation></Reference><Reference><Citation>Shirbhate E, Pandey J, Patel VK, et al. Understanding the role of ACE‐2 receptor in pathogenesis of COVID‐19 disease: a potential approach for therapeutic intervention. Pharmacol Rep. 2021;73(6):1539‐1550.</Citation></Reference><Reference><Citation>Zou X, Chen K, Zou J, et al. Single‐cell RNA‐seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019‐nCoV infection. Front Med. 2020;14(2):185‐192.</Citation></Reference><Reference><Citation>Zhang HB, Penninger JM, Li YM, et al. Angiotensin‐converting enzyme 2 (ACE2) as a SARS‐CoV‐2 receptor: molecular mechanisms and potential therapeutic target. Intens Care Med. 2020;46(4):586‐590.</Citation></Reference><Reference><Citation>Wang Z, Xu X. scRNA‐seq profiling of human testes reveals the presence of the ACE2 receptor, a target for SARS‐CoV‐2 infection in spermatogonia, leydig and sertoli cells. Cells. 2020;9(4):920.</Citation></Reference><Reference><Citation>Turner AJ, Hiscox JA, Hooper NM. ACE2: from vasopeptidase to SARS virus receptor. Trends Pharmacol Sci. 2004;25(6):291‐294.</Citation></Reference><Reference><Citation>Qi J, Zhou Y, Hua J, et al. The scRNA‐seq expression profiling of the receptor ACE2 and the cellular protease TMPRSS2 reveals human organs susceptible to SARS‐CoV‐2 infection. Int J Environ Res Public Health. 2021;18(1):284.</Citation></Reference><Reference><Citation>Imperio GE, Lye P, Mughis H, et al. Hypoxia alters the expression of ACE2 and TMPRSS2 SARS‐CoV‐2 cell entry mediators in hCMEC/D3 brain endothelial cells. Microvasc Res. 2021;138:104232.</Citation></Reference><Reference><Citation>Chen RR, Wang KE, Yu J, et al. The spatial and cell‐type distribution of SARS‐CoV‐2 receptor ACE2 in the human and mouse brains. Front Neurol. 2021;11:573095.</Citation></Reference><Reference><Citation>Li MY, Li L, Zhang Y, et al. Expression of the SARS‐CoV‐2 cell receptor gene ACE2 in a wide variety of human tissues. Infect Dis Poverty. 2020;9(1):45.</Citation></Reference><Reference><Citation>Khan S, Gomes J. Neuropathogenesis of SARS‐CoV‐2 infection. Elife. 2020;9:e59136.</Citation></Reference><Reference><Citation>Cui H, Su S, Cao Y, et al. The altered anatomical distribution of ACE2 in the brain with Alzheimer's disease pathology. Front Cell Dev Biol. 2021;9:684874.</Citation></Reference><Reference><Citation>Buzhdygan TP, DeOre BJ, Baldwin‐Leclair A, et al. The SARS‐CoV‐2 spike protein alters barrier function in 2D static and 3D microfluidic in‐vitro models of the human blood‐brain barrier. Neurobiol Dis. 2020;146:105131.</Citation></Reference><Reference><Citation>Hamming I, Timens W, Bulthuis MLC, et al. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol. 2004;203(2):631‐637.</Citation></Reference><Reference><Citation>Zhang L, Zhou L, Bao LL, et al. SARS‐CoV‐2 crosses the blood‐brain barrier accompanied with basement membrane disruption without tight junctions alteration. Sig Transduct Target Ther. 2021;6(1):337.</Citation></Reference><Reference><Citation>Hernandez VS, Zetter MA, Guerra EC, et al. ACE2 expression in rat brain: implications for COVID‐19 associated neurological manifestations. Exp Neurol. 2021;345:113837.</Citation></Reference><Reference><Citation>Dogbevia G, Grasshoff H, Othman A, et al. Brain endothelial specific gene therapy improves experimental Sandhoff disease. J Cerebr Blood F Met. 2020;40(6):1338‐1350.</Citation></Reference><Reference><Citation>Korbelin J, Dogbevia G, Michelfelder S, et al. A brain microvasculature endothelial cell‐specific viral vector with the potential to treat neurovascular and neurological diseases. Embo Mol Med. 2016;8(6):609‐625.</Citation></Reference><Reference><Citation>Li X, Zhang ZQ, Wang ZL, et al. Cell deaths: involvement in the pathogenesis and intervention therapy of COVID‐19. Sig Transduct Target Ther. 2022;7(1):186.</Citation></Reference><Reference><Citation>Ma HB, Zhu ZJ, Lin HP, et al. Pyroptosis of syncytia formed by fusion of SARS‐CoV‐2 spike and ACE2‐expressing cells. Cell Discov. 2021;7(1):73.</Citation></Reference><Reference><Citation>Da Silva MM, de Lucena ASL, Paiva SDL, et al. Cell death mechanisms involved in cell injury caused by SARS‐CoV‐2. Rev Med Virol. 2022;32(3):e2292.</Citation></Reference><Reference><Citation>Ren YJ, Shu T, Wu D, et al. The ORF3a protein of SARS‐CoV‐2 induces apoptosis in cells. Cell Mol Immunol. 2020;17(8):881‐883.</Citation></Reference><Reference><Citation>Kobayashi T, Masumoto J, Tada T, et al. Prognostic significance of the immunohistochemical staining of cleaved caspase‐3, an activated form of caspase‐3, in gliomas. Clin Cancer Res. 2007;13(13):3868‐3874.</Citation></Reference><Reference><Citation>Duan WR, Garner DS, Williams SD, et al. Comparison of immunohistochemistry for activated caspase‐3 and cleaved cytokeratin 18 with the TUNEL method for quantification of apoptosis in histological sections of PC‐3 subcutaneous xenografts. J Pathol. 2003;199(2):221‐228.</Citation></Reference><Reference><Citation>Yang Q, Wei XB, Deng B, et al. Cerebral small vessel disease alters neurovascular unit regulation of microcirculation integrity involved in vascular cognitive impairment. Neurobiol Dis. 2022;170:105750.</Citation></Reference><Reference><Citation>Jung W, Bollmann S, Lee J. Overview of quantitative susceptibility mapping using deep learning: current status, challenges and opportunities. Nmr Biomed. 2022;35(4):e4292.</Citation></Reference><Reference><Citation>Tang MY, Chen TW, Zhang XM, et al. GRE T2 *‐weighted MRI: principles and clinical applications. Biomed Res Int. 2014;2014:312142.</Citation></Reference><Reference><Citation>Charidimou A, Krishnan A, Werring DJ, et al. Cerebral microbleeds: a guide to detection and clinical relevance in different disease settings. Neuroradiology. 2013;55(6):655‐674.</Citation></Reference><Reference><Citation>Glushakova OY, Johnson D, Hayes RL. Delayed increases in microvascular pathology after experimental traumatic brain injury are associated with prolonged inflammation, blood‐brain barrier disruption, and progressive white matter damage. J Neurotrauma. 2014;31(13):1180‐1193.</Citation></Reference><Reference><Citation>Daneman R, Zhou L, Kebede AA, et al. Pericytes are required for blood‐brain barrier integrity during embryogenesis. Nature. 2010;468(7323):562‐566.</Citation></Reference><Reference><Citation>Nitta T, Hata M, Gotoh S, et al. Size‐selective loosening of the blood‐brain barrier in claudin‐5‐deficient mice. J Cell Biol. 2003;161(3):653‐660.</Citation></Reference><Reference><Citation>Douaud G, Lee S, Alfaro‐Almagro F, et al. SARS‐CoV‐2 is associated with changes in brain structure in UK Biobank. Nature. 2022;604(7907):697‐707.</Citation></Reference><Reference><Citation>Pelizzari L, Cazzoli M, Lipari S, et al. Mid‐term MRI evaluation reveals microstructural white matter alterations in COVID‐19 fully recovered subjects with anosmia presentation. Ther Adv Neurol Diso. 2022;15:17562864221111995.</Citation></Reference><Reference><Citation>Huang Y, Ling Q, Manyande A, et al. Brain Imaging changes in patients recovered from COVID‐19: a narrative review. Front Neurosci. 2022;16:855868.</Citation></Reference><Reference><Citation>Bourgonje AR, Abdulle AE, Timens W, et al. Angiotensin‐converting enzyme 2 (ACE2), SARS‐CoV‐2 and the pathophysiology of coronavirus disease 2019 (COVID‐19). J Pathol. 2020;251(3):228‐248.</Citation></Reference><Reference><Citation>Stein SR, Ramelli SC, Grazioli A, et al. SARS‐CoV‐2 infection and persistence in the human body and brain at autopsy. Nature. 2022;612(7941):758‐763.</Citation></Reference><Reference><Citation>Zhang DD, Cao Y, Mu JY, et al. Inflammatory biomarkers and cerebral small vessel disease: a community‐based cohort study. Stroke Vasc Neurol. 2022;7(4):302‐309.</Citation></Reference><Reference><Citation>Shoamanesh A, Preis SR, Beiser AS, et al. Inflammatory biomarkers, cerebral microbleeds, and small vessel disease: Framingham Heart Study. Neurology. 2015;84(8):825‐832.</Citation></Reference><Reference><Citation>Arba F, Giannini A, Piccardi B, et al. Small vessel disease and biomarkers of endothelial dysfunction after ischaemic stroke. Eur Stroke J. 2019;4(2):119‐126.</Citation></Reference><Reference><Citation>Walker KA, Power MC, Hoogeveen RC, et al. Midlife systemic inflammation, late‐life white matter integrity, and cerebral small vessel disease: the atherosclerosis risk in communities study. Stroke. 2017;48(12):3196‐3202.</Citation></Reference><Reference><Citation>Cao Y, Su N, Zhang D, et al. Correlation between total homocysteine and cerebral small vessel disease: a Mendelian randomization study. Eur J Neurol. 2021;28(6):1931‐1938.</Citation></Reference><Reference><Citation>Ji Y, Li X, Teng Z, et al. Homocysteine is associated with the development of cerebral small vessel disease: retrospective analyses from neuroimaging and cognitive outcomes. J Stroke Cerebrovasc Dis. 2020;29(12):105393.</Citation></Reference><Reference><Citation>Zhuo JM, Portugal GS, Kruger WD, et al. Diet‐induced hyperhomocysteinemia increases amyloid‐beta formation and deposition in a mouse model of Alzheimer's disease. Curr Alzheimer Res. 2010;7(2):140‐149.</Citation></Reference><Reference><Citation>Lu Y, Shen R, Zhu H, et al. Tandem mass tag (TMT) quantitative proteomic analysis of serum exosomes in cerebral small‐vessel disease (CSVD) patients with depressive symptoms. Curr Neurovasc Res. 2022;19(5):449‐461.</Citation></Reference><Reference><Citation>Del Cuore A, Pacinella G, Riolo R, et al. The role of immunosenescence in cerebral small vessel disease: a review. Int J Mol Sci. 2022;23(13):7136.</Citation></Reference><Reference><Citation>Anderson CD, Falcone GJ, Phuah CL, et al. Genetic variants in CETP increase risk of intracerebral hemorrhage. Ann Neurol. 2016;80(5):730‐740.</Citation></Reference><Reference><Citation>Gris JC, Quere I, Dechaud H, et al. High frequency of protein Z deficiency in patients with unexplained early fetal loss. Blood. 2002;99(7):2606‐2608.</Citation></Reference><Reference><Citation>Kang J, Luo W, Zhang C, et al. Positive association between serum insulin‐like growth factor‐1 and cognition in patients with cerebral small vessel disease. J Stroke Cerebrovasc Dis. 2021;30(7):105790.</Citation></Reference><Reference><Citation>Tondo G, Perani D, Comi C. TAM receptor pathways at the crossroads of neuroinflammation and neurodegeneration. Dis Markers. 2019;2019:2387614.</Citation></Reference><Reference><Citation>Filbin MR, Mehta A, Schneider AM, et al. Longitudinal proteomic analysis of severe COVID‐19 reveals survival‐associated signatures, tissue‐specific cell death, and cell‐cell interactions. Cell Rep Med. 2021;2(5):100287.</Citation></Reference><Reference><Citation>Shen B, Yi X, Sun Y, et al. Proteomic and metabolomic characterization of COVID‐19 patient sera. Cell. 2020;182(1):59‐72.</Citation></Reference><Reference><Citation>Peter RS, Nieters A, Krausslich HG, et al. Post‐acute sequelae of covid‐19 six to 12 months after infection: population based study. BMJ. 2022;379:e071050.</Citation></Reference><Reference><Citation>Logue JK, Franko NM, McCulloch DJ, et al. Sequelae in adults at 6 months after COVID‐19 infection. JAMA Netw Open. 2021;4(2):e210830.</Citation></Reference><Reference><Citation>Antonelli M, Pujol JC, Spector TD, et al. Risk of long COVID associated with delta versus omicron variants of SARS‐CoV‐2. Lancet. 2022;399(10343):2263‐2264.</Citation></Reference><Reference><Citation>Wang Q, Zhang Y, Wu L, et al. Structural and functional basis of SARS‐CoV‐2 entry by using human ACE2. Cell. 2020;181(4):894‐904.</Citation></Reference><Reference><Citation>Mohapatra RK, Tiwari R, Sarangi AK, et al. Twin combination of Omicron and Delta variants triggering a tsunami wave of ever high surges in COVID‐19 cases: a challenging global threat with a special focus on the Indian subcontinent. J Med Virol. 2022;94(5):1761‐1765.</Citation></Reference><Reference><Citation>Song ER, Zhang C, Israelow B, et al. Neuroinvasion of SARS‐CoV‐2 in human and mouse brain. J Exp Med. 2021;218(3):e20202135.</Citation></Reference><Reference><Citation>Torices S, Motta C, da Rosa B, et al. SARS‐CoV‐2 infection of human brain microvascular endothelial cells leads to inflammatory activation through NF‐kappaB non‐canonical pathway and mitochondrial remodeling. Preprint. bioRxiv. 2022;2022.06.16.496324.</Citation></Reference><Reference><Citation>Chen Y, Yang W, Chen F, et al. COVID‐19 and cognitive impairment: neuroinvasive and blood‒brain barrier dysfunction. J Neuroinflammation. 2022;19(1):222.</Citation></Reference><Reference><Citation>Li Y, Li M, Zuo L, et al. Cerebral microbleeds are associated with widespread blood‐brain barrier leakage. Eur Neurol. 2023;86(6):395‐403.</Citation></Reference><Reference><Citation>Li Y, Li M, Zhang X, et al. Higher blood‐brain barrier permeability is associated with higher white matter hyperintensities burden. J Neurol. 2017;264(7):1474‐1481.</Citation></Reference><Reference><Citation>Li M, Li Y, Zuo L, et al. Increase of blood‐brain barrier leakage is related to cognitive decline in vascular mild cognitive impairment. BMC Neurol. 2021;21(1):159.</Citation></Reference><Reference><Citation>Greene C, Connolly R, Brennan D, et al. Blood‐brain barrier disruption and sustained systemic inflammation in individuals with long COVID‐associated cognitive impairment. Nat Neurosci. 2024;27(3):421‐432.</Citation></Reference><Reference><Citation>Du M, Ma Y, Deng J, et al. Comparison of long COVID‐19 caused by different SARS‐CoV‐2 strains: a systematic review and meta‐analysis. Int J Environ Res Public Health. 2022;19(23):16010.</Citation></Reference><Reference><Citation>Huang F. Ursodeoxycholic acid as a potential alternative therapeutic approach for neurodegenerative disorders: effects on cell apoptosis, oxidative stress and inflammation in the brain. Brain Behav Immun Health. 2021;18:100348.</Citation></Reference><Reference><Citation>West RJH, Ugbode C, Fort‐Aznar L, et al. Neuroprotective activity of ursodeoxycholic acid in CHMP2B(Intron5) models of frontotemporal dementia. Neurobiol Dis. 2020;144:105047.</Citation></Reference><Reference><Citation>Wang Z, Chen Q, Chen J, et al. Risk factors of cerebral small vessel disease: a systematic review and meta‐analysis. Medicine (Baltimore). 2021;100(51):e28229.</Citation></Reference><Reference><Citation>Han F, Zhai FF, Wang Q, et al. Prevalence and Risk factors of cerebral small vessel disease in a Chinese population‐based sample. J Stroke. 2018;20(2):239‐246.</Citation></Reference><Reference><Citation>Ramphul K, Lohana P, Ramphul Y, et al. Hypertension, diabetes mellitus, and cerebrovascular disease predispose to a more severe outcome of COVID‐19. Arch Med Sci Atheroscler Dis. 2021;6:e30‐e39.</Citation></Reference><Reference><Citation>Lippi G, Wong J, Henry BM. Hypertension in patients with coronavirus disease 2019 (COVID‐19): a pooled analysis. Pol Arch Intern Med. 2020;130(4):304‐309.</Citation></Reference><Reference><Citation>Perl DP, Folkerth RD, Nath A. Microvascular injury in the brains of patients with Covid‐19. New Engl J Med. 2021;384(5):481‐483.</Citation></Reference><Reference><Citation>Elliott S, Lowe P, Symonds A. The possible influence of micro‐organisms and putrefaction in the production of GHB in post‐mortem biological fluid. Forensic Sci Int. 2004;139(2‐3):183‐190.</Citation></Reference><Reference><Citation>Lee Goff M. Early post‐mortem changes and stages of decomposition in exposed cadavers. Exp Appl Acarol. 2009;49(1‐2):21‐36.</Citation></Reference><Reference><Citation>Ostergaard L. SARS CoV‐2 related microvascular damage and symptoms during and after COVID‐19: consequences of capillary transit‐time changes, tissue hypoxia and inflammation. Physiol Rep. 2021;9(3):e14726.</Citation></Reference><Reference><Citation>Klein J, Wood J, Jaycox JR, et al. Distinguishing features of long COVID identified through immune profiling. Nature. 2023;623(7985):139‐148.</Citation></Reference><Reference><Citation>Lu X, Lin Z. COVID‐19, economic impact, mental health, and coping behaviors: a conceptual framework and future research directions. Front Psychol. 2021;12:759974.</Citation></Reference><Reference><Citation>Lamontagne SJ, Winters MF, Pizzagalli DA, et al. Post‐acute sequelae of COVID‐19: evidence of mood &amp; cognitive impairment. Brain Behav Immun Health. 2021;17:100347.</Citation></Reference><Reference><Citation>Khateeb J, Li Y, Zhang H. Emerging SARS‐CoV‐2 variants of concern and potential intervention approaches. Crit Care. 2021;25(1):244.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>